ALNY’s Q2 Miss and 2026 Guidance Cut Signal Scaling Challenges, Validating Bear Case Risks

What happened

Alnylam’s Q2 earnings and revenue missed estimates, and management cut its 2026 product sales guidance, overshadowing record Amvuttra sales. The 28% stock plunge indicates the market is rapidly repricing for a slower ATTR-CM ramp, directly challenging the smooth scaling thesis. This development shifts the probability weight toward the bear scenario, where combined net product revenue falls below $4.9 billion amid competitive pressure and potential gross-to-net headwinds. The subpoena overhang and aggressive Attruby uptake further cloud the outlook. The prior base-case value of $360 is now unlikely, with the stock at risk of declining toward the $260 bear implication.

Implication

The Q2 miss and guidance cut directly undermine the base-case assumption of $5.1B in FY2026 net product revenue, making the bear scenario ($260) more probable. With the stock now likely below $300, the attractive entry point may no longer hold as a floor if fundamentals deteriorate further. Competitive dynamics with BridgeBio’s Attruby and potential gross-to-net headwinds from the subpoena could prolong pressure. The market will now demand evidence of stabilized Amvuttra cadence and restored guidance credibility before re-rating. Until then, position sizing should be reduced and the WAIT rating remains warranted, with downside risk to $260.

Thesis delta

The investment thesis shifts from 'WAIT for cadence proof' to a broken thesis requiring significant reassessment. The Q2 miss and 2026 guidance cut materially reduce confidence in the FY2026 execution bar and the smooth ATTR-CM scaling narrative. The bear case—priced at $260—now looks more probable, and the prior $300 attractive entry is at risk of being breached.